Intrathecal treatment with the anti-phosphorylcholine monoclonal antibody TEPC-15 decreases neuronal damage in experimental pneumococcal meningitis

Chemotherapy

Volumn 58, Issue 3, 2012, Pages 212-216

  Gerber, Joachim ^a,b   Redlich, Sandra ^b   Ribes, Sandra ^b   Tauber, Simone C ^d   Schmidt, Holger ^c   Nau, Roland ^b,e  

^a Diana Hospital   (Germany)

^b Department of Neuropathology ^*  (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e Sleep Laboratory   (Germany)

Author keywords

Lipoteichoic acid; Meningitis; Neuronal injury; Streptococcus pneumoniae

Indexed keywords

CEFTRIAXONE; LIPOTEICHOIC ACID; MONOCLONAL ANTIBODY; PHOSPHORYLCHOLINE; TEICHOIC ACID; TEPC 15; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PHAGOCYTOSIS; CONTROLLED STUDY; DENTATE GYRUS; EXPERIMENTAL STUDY; HIPPOCAMPUS; IN VITRO STUDY; LACTATE BLOOD LEVEL; LEUKOCYTE COUNT; MICROGLIA; MOUSE; NERVE CELL LESION; NONHUMAN; PNEUMOCOCCAL MENINGITIS; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; CEFTRIAXONE; CELLS, CULTURED; DENTATE GYRUS; DISEASE MODELS, ANIMAL; LACTIC ACID; LEUKOCYTES; LIPOPOLYSACCHARIDES; MENINGITIS, PNEUMOCOCCAL; MICE; MICE, INBRED C57BL; MICROGLIA; PHAGOCYTOSIS; PROSTAGLANDINS; PROTEINS; RABBITS; STREPTOCOCCUS PNEUMONIAE; TEICHOIC ACIDS;

EID: 84863097044     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000337287     Document Type: Article

References (16)

1. Nau R, Brück W: Neuronal injury in bacterial meningitis: mechanisms and implications for therapy. Trends Neurosci 2002;25:38-45. (Pubitemid 34093784)
2. Leib SL, Kim YS, Chow LL, Sheldon RA, Täuber MG: Reactive oxygen intermediates contribute to necrotic and apoptotic neuronal injury in an infant rat model of bacterial meningitis due to group B Streptococci. J Clin Invest 1996;98:2632-2639. (Pubitemid 26415086)
3. Kim YS, Täuber MG: Neurotoxicity of glia activated by gram-positive bacterial products depends on nitric oxide production. Infect Immun 1996;64:3148-3153. (Pubitemid 26256158)
4. Ribes S, Ebert S, Regen T, Agarwal A, Tauber SC, Czesnik D, Spreer A, Bunkowski S, Eiffert H, Hanisch UK, Hammerschmidt S, Nau R: Toll-like receptor stimulation enhances phagocytosis and intracellular killing of nonencapsulated and encapsulated Streptococcus pneumoniae by murine microglia. Infect Immun 2010;78:865-871.
5. Tuomanen E, Liu H, Hengstler B, Zak O, Tomasz A: The induction of meningeal inflammation by components of the pneumococcal cell wall. J Infect Dis 1985;151:859-868. (Pubitemid 15094604)
6. Gerber J, Pohl K, Sander V, Bunkowski S, Nau R: Rifampin followed by ceftriaxone for experimental meningitis decreases lipoteichoic acid concentrations in cerebrospinal fluid and reduces neuronal damage in comparison to ceftriaxone alone. Antimicrob Agents Chemother 2003;47:1313-1317. (Pubitemid 36368591)
7. Nau R, Wellmer A, Soto A, Koch K, Schneider O, Schmidt H, Gerber J, Michel U, Brück W: Rifampicin reduces early mortality in experimental Streptococcus pneumoniae meningitis. J Infect Dis 1999;179:1557-1560. (Pubitemid 29246610)
8. Spreer A, Lugert R, Stoltefaut V, Hoecht A, Eiffert H, Nau R: Short-term rifampicin pretreatment reduces inflammation and neuronal cell death in a rabbit model of bacterial meningitis. Crit Care Med 2009;37:2253-2258.
9. Grandgirard D, Oberson K, Bühlmann A, Gäumann R, Leib SL: Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis. Antimicrob Agents Chemother 2010;54:1323-1326.
10. Grandgirard D, Schürch C, Cottagnoud P, Leib SL: Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Antimicrob Agents Chemother 2007;51:2173-2178. (Pubitemid 46903110)
11. Xu K, Wang H, Liu L, Xu W, Sheng J, Fan W, Yang YY, Li L: Efficacy of CG3R6 TAT nanoparticles self-assembled from a novel antimicrobial peptide for the treatment of Candida albicans meningitis in rabbits. Chemotherapy 2011;57:417-425.
12. Sparo MD, Jones DG, Sánchez Bruni SF: Assessment of the in vitro efficacy of the novel antimicrobial peptide CECT7121 against human gram-positive bacteria from serious infections refractory to treatment. Chemotherapy 2009;55:270-277.
13. Schmidt H, Tlustochowska A, Stuertz K, Djukic M, Gerber J, Schütz E, Kuhnt U, Nau R: Organotypic hippocampal cultures. A model of brain tissue damage in Streptococcus pneumoniae meningitis. J Neuroimmunol 2001;113:30-39. (Pubitemid 32008669)
14. Braun JS, Sublett JE, Freyer, Mitchell TJ, Cleveland JL, Tuomanen EI, Weber JR: Pneumococcal pneumolysin and H 2 O 2 mediate brain cell apoptosis during meningitis. J Clin Invest 2002;109:19-27. (Pubitemid 34052538)
15. Davson H, Welch K, Segal MB: Physiology and Pathophysiology of the Cerebrospinal Fluid. Edinburgh, Churchill Livingstone, 1987.
16. Rennels ML, Gregory TF, Blaumanis OR, Fujimoto K, Grady PA: Evidence for a 'paravascular' fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain Res 1985;326:47-63. (Pubitemid 15160009)